Bio tech company updates — 10/24/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
South Korean biotech firms experienced significant stock volatility this week, driven by a mix of successful overseas partnerships and clinical trial setbacks. While Samsung Biologics saw analyst upgrades following record quarterly results, other companies like Sam Chun Dang Pharm faced severe market value losses. Meanwhile, regional hubs like Songdo are pivoting toward AI-driven drug discovery, and EuBiologics received a high-profile visit from the WHO Director-General.
Key Findings
Korean biotechnology sectors faced divergent market movements in the last 24 hours. While some companies benefited from new overseas contracts, others suffered sharp declines due to trial failures. Samsung Biologics emerged as a standout performer, with brokerages raising price targets significantly. Concurrently, policy and infrastructure developments in Korea’s bio-clusters shifted focus toward AI integration and global vaccine supply chains.
Details
Market Volatility and Corporate Performance The Korean biotech market saw a "whipsaw" effect as overseas deals boosted some stocks while clinical trial setbacks dragged others down. In contrast, Samsung Biologics received strong support from the financial sector, with six out of ten brokerages setting a new target price of 2 million won following record third-quarter results. This implies a potential 41% upside for the stock.
Conversely, Sam Chun Dang Pharm Co. experienced a severe sell-off, erasing approximately 10 trillion won ($6.6 billion) in market value over just two trading sessions.
Regional Hubs and Infrastructure Shifts Incheon’s Songdo International Business District is undergoing a strategic pivot from traditional contract biomanufacturing to AI-driven drug discovery. This transition is supported by major industry players, including Samsung Biologics and Eli Lilly, which are backing a new startup hub in the region.
Additionally, Gangwon Technopark hosted a seminar on October 22 focused on expanding regional bio-infrastructure through foodtech and microbiome research, aiming to leverage local university resources for breakthroughs.
Global Engagement and Vaccine Sector Korean vaccine manufacturer EuBiologics received a visit from WHO Director-General Tedros Adhanom Ghebreyesus at its second plant in Chuncheon, Gangwon Province. The visit highlights EuBiologics’ efforts to expand its international supply business beyond cholera vaccines, aiming for the global typhoid market.
Sources
Korea biotech swings as overseas deals lift some stocks while trials hit others - CHOSUNBIZ
Biotech - KED Global
Korean Biotech Draws 1.9 Trillion Won, Topping All of Last Year - Seoul Economic Daily
Korean Biotech
koreabiomed.com
en.sedaily.com
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
